RxDoctor Payments Data

Teresa Tarrant, MD

Rheumatology · Chapel Hill, NCNPI 1649331653

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 22.9%. 2025 is the largest year on record at $32,367, more than ten times the $1,722 reported in 2019. Among rheumatology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$63,253in general payments, 2019–2025

Across 33 payments — averaging $1916.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$14K
  • Chiesi USA, Inc.$14K
  • Pfizer$12K
  • X4 Pharmaceuticals, Inc.$10K
  • Argenx US, Inc.$10K
  • Phadia GmbH$2K
  • plus $1K from 4 others
$469,932in research payments, 2019–2025

Across 10 payments — averaging $46,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$440K
  • AbbVie$30K

What the payments were for

  • Consulting fees$31,41850%
  • Speaking & faculty fees$28,63845%
  • Travel & lodging$2,3884%
  • Food & beverage$8101%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,253 in reported general payments places this provider in the 90th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$11,105
Medicare patients
66
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept53$401,583
RinvoqUpadacitinib19$116,841
OtezlaApremilast14$67,269
OrenciaAbatacept11$64,186
Leflunomide27$2,952
Hydroxychloroquine Sulfate49$1,985
Cevimeline Hcl11$1,347
MethotrexateMethotrexate Sodium42$994
Prednisone61$453
Tramadol Hcl14$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Orencia$938$64,18611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →